134 completed, 31 unknown, 22 recruiting, 14 terminated. 64 Phase 4, 47 Phase 3, 42 Phase 1, 31 Not applicable, 27 Phase 2.
Follow Tamsulosin: new trials by email Literature Review of Tamsulosin trials Research Report on Tamsulosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial) Tamsulosin hydrochloride 0.2 mg, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Shanghai East Hospital | 400 | 2026-12-01 | 2026-09-29 |
| A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate) Vesomni - Benign Prostatic Hyperplasia | Not yet recruiting | Astellas Pharma Korea, Inc. | 600 | 2026-11-30 | 2026-10-15 | |
| Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule - Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | Il-Yang Pharm. Co., Ltd. | 660 | 2026-11-09 | 2026-10-13 |
| Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery Uroselective alpha-1-adrenergic receptor antagonist, Placebo - Urinary Retention Postoperative | Phase 4 | Recruiting | Mayo Clinic | 20 | 2026-10-01 | 2026-06-29 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| The Effect of Acupuncture on Passing Ureteral Stones medical expulsive therapy (tamsulosin), Acupuncture - Ureter Calculi | Not applicable | Recruiting | Hitit University | 40 | 2026-08-01 | 2026-10-26 |
| Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 90 | 2026-07-01 | 2026-07-23 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones L-Citrulline, Tamsulosin - Distal Ureteral Stone, Urolithiasis | Phase 2 | Recruiting | Beni-Suef University | 120 | 2026-05-06 | 2026-06-01 |
| Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS Tamsulosin, Placebo Capsule, Intraureteral Aminophylline - Renal Stones, Retrograde Intrarenal Surgery | Phase 2 | Recruiting | Beni-Suef University | 322 | 2026-05-06 | 2026-06-03 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion Mirabegron, Tamsulosin - Ureteral Calculi | Phase 4 | Recruiting | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 500 | 2026-02-13 | 2026-10-01 |
| Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed Conditions Tamsulosin 0.4 mg ER tablet - Bioequivalence | Not applicable | Completed | ADIUM | 66 | 2026-02-12 | 2026-07-13 |
| Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy Tamsulosin 0.2mg - Acute Urinary Retention, LUTS(Lower Urinary Tract Symptoms) | Phase 4 | Not yet recruiting | Peking University First Hospital | 1844 | 2026-02-01 | 2025-12-23 |
| Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg Tamsulosin - Kidney Stone, Ureteric Stone | Not applicable | Recruiting | Ain Shams University | 140 | 2025-12-01 | 2026-05-01 |
| A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions Tamsulosin (0.4 mg/j) - Healthy Volunteer Male Subjects | Phase 1 | Recruiting | Berlin-Chemie AG Menarini Group | 46 | 2025-09-08 | 2025-10-03 |
| Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms Tamsulosin Hydrochloride 0.4 mg, Solifenacin Succinate 5 mg, Mirabegron 25 mg - Ureteral Stent-Related Symptom | Phase 3 | Recruiting | Bir Hospital | 189 | 2025-08-30 | 2025-09-08 |
| A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions Tamsulosin (0.4 mg/j) - Healthy Volunteers, Male | Phase 1 | Active not recruiting | Berlin-Chemie AG Menarini Group | 46 | 2025-06-16 | 2025-08-08 |
Showing 20 of 218. Sign in to see all of them.
Prostatic Hyperplasia (85) · Lower Urinary Tract Symptoms (30) · Urinary Retention (17) · Urinary Bladder, Overactive (12) · Ureterolithiasis (11) · Kidney Calculi (10) · Ureteral Calculi (8) · Urolithiasis (7) · Erectile Dysfunction (6) · Nephrolithiasis (6) · Prostatic Neoplasms (3) · Renal Colic (3) · Urinary Bladder, Neurogenic (3) · Urinary Incontinence (3) · Urinary Tract Infections (3)
Boehringer Ingelheim (21) · GlaxoSmithKline (13) · Mansoura University (8) · Astellas Pharma Inc (7) · Ain Shams University (6) · Astellas Pharma Europe B.V. (6) · Beni-Suef University (6) · Eli Lilly and Company (4) · Samsung Medical Center (4) · Assiut University (3) · Berlin-Chemie AG Menarini Group (3) · Chong Kun Dang Pharmaceutical (3) · Jeil Pharmaceutical Co., Ltd. (3) · Xintian Pharmaceutical (3) · Albert Einstein Healthcare Network (2)
United States (49) · South Korea (27) · Egypt (26) · United Kingdom (14) · Canada (13) · Germany (13) · France (11) · Italy (11) · China (9) · Poland (9) · Spain (9) · Belgium (8) · Netherlands (8) · Russia (7) · Taiwan (7)
Hany F Badawy, MD (2) · Min Gul Kim, PhD (2) · Shougher Heboyan, MD (2) · Zhongguo Chen, MD (2) · Abdullatif AL-Terki, MD (1) · Ahmed Elhefnawy (1)
PMID 10851208, PMID 11756098, PMID 11927799, PMID 12072644, PMID 12119802, PMID 12923400, PMID 15126771, PMID 15738343, PMID 16391172, PMID 16465187, PMID 16533484, PMID 17011944, PMID 17102958, PMID 17105794, PMID 18426998, PMID 18461049, PMID 19047577, PMID 19375849, PMID 19738158, PMID 21109344, PMID 21149761, PMID 21789068, PMID 21791356, PMID 22266271, PMID 22297243, PMID 22801444, PMID 22831853, PMID 23018163, PMID 23170127, PMID 23266540, PMID 23346990, PMID 23537687, PMID 2466358, PMID 24725169, PMID 25530364, PMID 25613154, PMID 25712312, PMID 26299520, PMID 26429522, PMID 26453222, PMID 27890522, PMID 27908918, PMID 28029383, PMID 28800206, PMID 29044968, PMID 29394114, PMID 29490509, PMID 29913020, PMID 30607798, PMID 31148056
2008 (2), 2009 (2), 2015 (1), 2016 (1), K12DK111028 (1), U01DK065209 (1), U01DK071603 (1), U01DK096037 (1), U34DK090957 (1)